Activating mutations in the epidermal growth factor receptor (EGFR) gene were detected in 15%–20% of patients with NSCLC, primarily in adenocarcinoma patients without smoking history and Asian patients (Jänne et al., 2005). This evidence concerns the gene EGFR and adenocarcinoma.